Chinese Pen Injector Innovator Hanerxi Completes Tens of Millions RMB Pre-A Funding Round with Independent IP to Break Overseas Monopoly

VCBeat has learned at the earliest opportunity that,Suzhou Hanerxi Medical Device Development Co., Ltd.: A Leading Global Provider of Chinese Pen Injectors（Abbreviated as Hanerxi）RecentlyAnnouncementCompleted RMB 10 Million PRe-Series A financing, byQianhui CapitalLead investor. Previously，HanseiReceived investments from CCB Medical Growth Fund and Kun Gaoxin Venture Capital.

Hansy was founded inIn 2014, dedicated to the research and development of pen injectors (injection pens).Injection pens are high-precision syringes designed specifically for medications in cartridge vials.，It features precise quantitative injection, enables self-administered medical treatment, and is safe and convenient to use.The scope of use includes: self-administered treatment for chronic diseases, such as insulin and growth hormone; precision medication, such as interferon, various cell therapies, gene therapies, and biologics; and high-end cosmetic injections used in consumer healthcare settings.

Taking insulin as an example, in this fieldGlobal Demand for Injection Pens Is200 million units(Standard Pen) to2.5 billion units (disposable pens), representing a market size of RMB 12–50 billion.

The market for injection pens is substantial, yet high barriers to entry make it difficult for startups to enter the field. For instance, there are over 1,500 patents related to the structure of injection pens, the vast majority of which have been preemptively registered by foreign companies. This has significantly hindered independent research and development of injection pens in China.

To break the overseas monopoly,Hansel has undergone nearly10 Years of R&D,Finally"Production of products with independent intellectual property rights"Fully AutomaticPen Injector: Safe Performance and Stable Quality，YesOn Par with Global StandardsTop-Tier Products。

Hansei's Self-Developed Injection Pen,Utilizes high-lubricity materials for a smooth injection experience; features an originator-developed foundational structure with expandable structural patents; dosage adjustment includes both scale display and tactile (blind) operation capability; standard model with replaceable cartridge design, designed for5,000 actuations, ensuring over 2,000 precise injections; disposable pen device, designed for 500 actuations, ensuring over 100 precise injections.

 （Hanse Product Image）

Hanerxi CEO Chu YaoqiangIndicates:“This injection pen has beenIn 2020, it obtained the medical device registration certificate issued by the National Medical Products Administration (NMPA), with current production capacity reaching 500,000 units. This financing will help the company introduce automated production equipment and implement large-scale automated manufacturing.ImplementationAnnual Production Capacity of Injection Pens Exceeds Target10 million units。“This means that China’s independent-brand injection pens will be globally competitive in both performance and price. Meanwhile, domestically produced injection pens will accelerate the R&D and manufacturing of biologics in China, benefiting more patients, and introduce another Chinese independent brand to the global biopharmaceutical industry.”

VCBeat has learned that a well-known domestic biopharmaceutical company has completed due diligence on Hanerxi, highly recognizing the independence of Hanerxi’s injection pen in terms of global intellectual property rights. The two parties are expected to join hands to boost the global sales of Chinese biologics.

Chu Yaoqiang revealed:“Hanseer is actively expanding its domestic and international markets. Leveraging its advantages in drug delivery design, the company provides customers with more comprehensive customized solutions to support the development of China’s innovative pharmaceutical industry. Meanwhile, Hanseer is diligently implementing its global strategy, aiming to promote the worldwide sales of Chinese-made pharmaceuticals through collaborations with major pharmaceutical companies and to establish Hanseer as an international brand for injection pens.”

With the development of biopharmaceuticals, pen injectorsThe application areas have expanded significantly, including the use of various hormones such as somatotropin and Gonal-F, as well as adalimumab, bevacizumab, nivolumab, etanercept,a key component of several blockbuster drug formulations, including GLP-1 receptor agonists. Currently, numerous biopharmaceutical companies both in China and abroad are developing multiple new drugs or biosimilars in these areas, with some having already obtained or on the verge of receiving marketing approval.

Chu Yaoqiang stated:“Hanshi willPen Injector-BasedAccelerate support for the development of the biopharmaceutical industry, reduce medication costs, and improve public health and medical care standards.”

Qianhui Capital is an emerging venture capital firm based in Suzhou, primarily investing in growth-stage projects in the fields of healthcare, new materials, and new energy. The fund boasts several professionals with master’s and doctoral degrees, demonstrating outstanding investment research capabilities. Its founder, Mr. Chang Yubao, has over a decade of executive experience at renowned investment institutions and has participated in and successfully exited dozens of IPO projects, accumulating extensive investment expertise. Qianhui Capital’s substantial single-round investment in Hanerxi during its Pre-A round reflects strong recognition from the capital market of the company’s team, products, and market value.